糖尿病患者的血清白蛋白球蛋白比值与全因及特定原因死亡率的相关性
该前瞻性研究纳入1999至2018年美国国家健康与营养调查中8508名糖尿病成人,随访至2019年12月31日,采用加权Cox比例风险模型分析血清白蛋白球蛋白比值(AGR)与全因、心血管病及癌症死亡率的关系。结果发现较高的血清AGR水平与全因及特定原因死亡率降低呈显著线性剂量反应关系。
要点
- 血清AGR最高四分位组全因死亡风险显著低于最低组,HR为0.51(95%CI 0.42-0.60)。
- 血清AGR最高四分位组心血管病死亡HR为0.62(95%CI 0.46-0.83),癌症死亡HR为0.57(95%CI 0.39-0.85)。
- 血清AGR经自然对数转换后每升高1单位,全因死亡风险降低73%,心血管病死亡风险降低60%,癌症死亡风险降低63%。
核心结论
- AGR是预测糖尿病患者长期死亡风险的有前景的生物标志物,尤其在年龄小于60岁和重度饮酒者中。
研究设计与样本
- 前瞻性研究,纳入1999至2018年美国国家健康与营养调查(NHANES)中8508名糖尿病成人,通过链接至2019年12月31日的国家死亡索引记录确定死亡结局。
主要发现
- 平均随访9.61年期间,共记录2415例全因死亡,包括688例心血管病死亡和413例癌症死亡。
- 多变量调整后,较高的血清AGR水平与全因及特定原因死亡率降低呈显著线性剂量反应关系(全因死亡Ptrend < .0001,心血管病死亡Ptrend < .001,癌症死亡Ptrend < .01)。
- 血清AGR最高四分位组全因死亡的多变量调整HR为0.51(95%CI 0.42-0.60),心血管病死亡HR为0.62(95%CI 0.46-0.83),癌症死亡HR为0.57(95%CI 0.39-0.85)。
- 血清AGR经自然对数转换后每升高1单位,全因死亡风险降低73%,心血管病死亡风险降低60%,癌症死亡风险降低63%(所有P < .001)。
- 分层分析和敏感性分析均显示相同关系。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: There are insufficient data to support a link between serum albumin-to-globulin ratio (AGR) and mortality in individuals with diabetes. OBJECTIVE: This prospective study sought to investigate the relationship between serum AGR and all-cause and cause-specific mortality in adult diabetics. METHODS: This study included 8508 adults with diabetes from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018. Death outcomes were ascertained by linkage to National Death Index records through December 31, 2019. Hazard ratios (HR) and 95% CIs for mortality from all causes, cardiovascular disease (CVD), and cancer were estimated using weighted Cox proportional-hazards models. RESULTS: A total of 2415 all-cause deaths, including 688 CV deaths and 413 cancer deaths, were recorded over an average of 9.61 years of follow-up. After multivariate adjustment, there was a significant and linear relationship between higher serum AGR levels and reduced all-cause and cause-specific mortality in a dose-response manner. The multivariate-adjusted HR and 95% CI for all-cause mortality (Ptrend < .0001), cardiovascular mortality (Ptrend < .001), and cancer mortality (Ptrend < .01) were 0.51 (0.42-0.60), 0.62 (0.46-0.83), and 0.57 (0.39-0.85), respectively, for individuals in the highest AGR quartile. There was a 73% decreased risk of all-cause death per 1-unit rise in natural log-transformed serum AGR, as well as a 60% and 63% decreased risk of mortality from CVD and cancer, respectively (all P < .001). Both the stratified analysis and the sensitivity analyses revealed the same relationships. CONCLUSION: AGR is a promising biomarker in risk predictions for long-term mortality in diabetic individuals, particularly in those younger than 60 years and heavy drinkers.
引用
- Wen H, Niu X, Yu R, et al. Association of Serum AGR With All-Cause and Cause-Specific Mortality Among Individuals With Diabetes. J Clin Endocrinol Metab. 2025. PMID: 38571296. doi:10.1210/clinem/dgae215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。